Meaningful weight loss and glycemic improvements often require 1216 weeks or longer, particularly at lower maintenance doses
If pancreatitis is suspected, tirzepatide should be promptly discontinued and not restarted if pancreatitis is confirmed
Diarrhea on tirzepatide and semaglutide can occur, especially during dose increases
Moreover, TZP induced a considerable average decrease of 53-55% in fasting glucagon levels (adjusted for fasting serum glucose), and a 16-24% decrease in HOMA2-IR, calculated with insulin, highlighting its superior effects on insulin sensitivity
The pharmacokinetic properties of semaglutide, while favorable for once-weekly dosing due to its extended half-life, were specifically optimized for this interval to maintain therapeutic drug levels